Cargando…

Revealing the structural and molecular interaction landscape of the favipiravir-RTP and SARS-CoV-2 RdRp complex through integrative bioinformatics: Insights for developing potent drugs targeting SARS-CoV-2 and other viruses

BACKGROUND: The global research community has made considerable progress in therapeutic and vaccine research during the COVID-19 pandemic. Several therapeutics have been repurposed for the treatment of COVID-19. One such compound is, favipiravir, which was approved for the treatment of influenza vir...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chakraborty, Chiranjib, Bhattacharya, Manojit, Saha, Abinit, Alshammari, Abdulrahman, Alharbi, Metab, Saikumar, G., Pal, Soumen, Dhama, Kuldeep, Lee, Sang-Soo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Authors. Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences. 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10170963/ https://www.ncbi.nlm.nih.gov/pubmed/37196368 http://dx.doi.org/10.1016/j.jiph.2023.05.010

Ejemplares similares

Natural selection of the D614G mutation in SARS-CoV-2 Omicron (B.1.1.529) variant and its subvariants
por: Chakraborty, Chiranjib, et al.
Publicado: (2023)

Designing an effective therapeutic siRNA to silence RdRp gene of SARS-CoV-2
por: Shawan, Mohammad Mahfuz Ali Khan, et al.
Publicado: (2021)

SARS-CoV-2 RdRp Inhibitors Selected from a Cell-Based SARS-CoV-2 RdRp Activity Assay System
por: Min, Jung Sun, et al.
Publicado: (2021)

Structure of the SARS-CoV-2 RNA-dependent RNA polymerase in the presence of favipiravir-RTP
por: Naydenova, Katerina, et al.
Publicado: (2021)

RdRp mutations are associated with SARS-CoV-2 genome evolution
por: Eskier, Doğa, et al.
Publicado: (2020)

The potential of Paritaprevir and Emetine as inhibitors of SARS-CoV-2 RdRp
por: Gurung, Arun Bahadur, et al.
Publicado: (2021)

Integrative Bioinformatics Approaches Indicate a Particular Pattern of Some SARS-CoV-2 and Non-SARS-CoV-2 Proteins
por: Chakraborty, Chiranjib, et al.
Publicado: (2022)

A novel mutation-proof, next-generation vaccine to fight against upcoming SARS-CoV-2 variants and subvariants, designed through AI enabled approaches and tools, along with the machine learning based immune simulation: A vaccine breakthrough
por: Bhattacharya, Manojit, et al.
Publicado: (2023)

Resistance to nirmatrelvir due to mutations in the Mpro in the subvariants of SARS-CoV-2 Omicron: Another concern?
por: Chatterjee, Srijan, et al.
Publicado: (2023)

Aging correlates with lower threshold cycle values for RdRP/RdRP+S genes during molecular detection of SARS-CoV-2
por: Mikuła-Pietrasik, Justyna, et al.
Publicado: (2021)

SARS-CoV-2 Vaccines, Vaccine Development Technologies, and Significant Efforts in Vaccine Development during the Pandemic: The Lessons Learned Might Help to Fight against the Next Pandemic
por: Chakraborty, Chiranjib, et al.
Publicado: (2023)

Recombinant SARS-CoV-2 variants XD, XE, and XF: The emergence of recombinant variants requires an urgent call for research – Correspondence
por: Chakraborty, Chiranjib, et al.
Publicado: (2022)

The SARS-CoV-2 Omicron recombinant subvariants XBB, XBB.1, and XBB.1.5 are expanding rapidly with unique mutations, antibody evasion, and immune escape properties – an alarming global threat of a surge in COVID-19 cases again?
por: Chakraborty, Chiranjib, et al.
Publicado: (2023)

Continent-wide evolutionary trends of emerging SARS-CoV-2 variants: dynamic profiles from Alpha to Omicron
por: Chakraborty, Chiranjib, et al.
Publicado: (2022)

XBB.1.5: A new threatening SARS-CoV-2 Omicron subvariant
por: Islam, Md. Aminul, et al.
Publicado: (2023)

Polyphenols as Potential Inhibitors of SARS-CoV-2 RNA Dependent RNA Polymerase (RdRp)
por: Wu, Yifei, et al.
Publicado: (2021)

Allosteric activation of SARS-CoV-2 RdRp by remdesivir triphosphate and other phosphorylated nucleotides
por: Wang, Bing, et al.
Publicado: (2021)

A hypothesis on designing strategy of effective RdRp inhibitors for the treatment of SARS-CoV-2
por: Chaube, Udit, et al.
Publicado: (2022)

Omicron variant (B.1.1.529) of SARS-CoV-2: understanding mutations in the genome, S-glycoprotein, and antibody-binding regions
por: Bhattacharya, Manojit, et al.
Publicado: (2022)

Molnupiravir’s mechanism of action drives “error catastrophe” in SARS-CoV-2: A therapeutic strategy that leads to lethal mutagenesis of the virus
por: Chatterjee, Srijan, et al.
Publicado: (2023)

A Detailed Overview of SARS-CoV-2 Omicron: Its Sub-Variants, Mutations and Pathophysiology, Clinical Characteristics, Immunological Landscape, Immune Escape, and Therapies
por: Chatterjee, Srijan, et al.
Publicado: (2023)

SARS-CoV-2 RNA Dependent RNA polymerase (RdRp) – A drug repurposing study
por: Ahmad, Jamshaid, et al.
Publicado: (2020)

Different selection dynamics of S and RdRp between SARS-CoV-2 genomes with and without the dominant mutations
por: Koçhan, Necla, et al.
Publicado: (2021)

Real-time PCR Ct value in SARS-CoV-2 detection: RdRp or N gene?
por: Abbasi, Hamidreza, et al.
Publicado: (2021)

Identification of Polyphenol Derivatives as Novel SARS-CoV-2 and DENV Non-Nucleoside RdRp Inhibitors
por: Gao, Shenghua, et al.
Publicado: (2022)

Composition of naturally occurring compounds decreases activity of Omicron and SARS-CoV-2 RdRp complex
por: Goc, Anna, et al.
Publicado: (2022)

Design, synthesis, docking, and biochemical characterization of non-nucleoside SARS-CoV-2 RdRp inhibitors
por: Brindani, Nicoletta, et al.
Publicado: (2023)

Immediate need for next-generation and mutation-proof vaccine to protect against current emerging Omicron sublineages and future SARS-CoV-2 variants: An urgent call for researchers and vaccine companies – Correspondence
por: Chakraborty, Chiranjib, et al.
Publicado: (2022)

D614G mutation eventuates in all VOI and VOC in SARS-CoV-2: Is it part of the positive selection pioneered by Darwin?
por: Chakraborty, Chiranjib, et al.
Publicado: (2021)

Favipiravir use for SARS CoV-2 infection
por: Boretti, Alberto
Publicado: (2020)

The D614G mutation helps to increase the transmissibility and reduce the virulence of SARS-CoV-2 variants through natural selection
por: Chakraborty, Chiranjib, et al.
Publicado: (2023)

Can the RBD mutation R346X provide an additional fitness to the “variant soup,” including offspring of BQ and XBB of SARS-CoV-2 Omicron for the antibody resistance?
por: Chatterjee, Srijan, et al.
Publicado: (2023)

Targeting 3CLpro and SARS-CoV-2 RdRp by Amphimedon sp. Metabolites: A Computational Study
por: Shady, Nourhan Hisham, et al.
Publicado: (2021)

Development of colorimetric sensors based on gold nanoparticles for SARS-CoV-2 RdRp, E and S genes detection
por: Rodríguez Díaz, Ciro, et al.
Publicado: (2022)

Effectiveness of Remdesivir in Comparison with Five Approved Antiviral Drugs for Inhibition of RdRp in Combat with SARS-CoV-2
por: Mahdian, Soodeh, et al.
Publicado: (2022)

Potential RNA-dependent RNA polymerase (RdRp) inhibitors as prospective drug candidates for SARS-CoV-2
por: Bekheit, Mohamed S., et al.
Publicado: (2023)

A duplex-specific nuclease based electrochemical biosensor for the assay of SARS-CoV-2 RdRp RNA
por: Zhou, Ke, et al.
Publicado: (2023)

A European perspective of phylogenomics, sublineages, geographical distribution, epidemiology, and mutational landscape of mpox virus: Emergence pattern may help to fight the next public health emergency in Europe
por: Chakraborty, Chiranjib, et al.
Publicado: (2023)

Detailed Molecular Interactions of Favipiravir with SARS-CoV-2, SARS-CoV, MERS-CoV, and Influenza Virus Polymerases In Silico
por: Sada, Mitsuru, et al.
Publicado: (2020)

Multiplex real-time RT-PCR method for the diagnosis of SARS-CoV-2 by targeting viral N, RdRP and human RP genes
por: Tombuloglu, Huseyin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_vmpcj24egsb8gm2cbqarl6suhl